Latest Content

Adding 177Lu-PSMA-617 to combination therapy improves disease control in PSMA+ mHSPC while maintaining quality of life and pain outcomes.

Dr. Ranee Mehra shares guidance on recurrence, quality-of-life concerns and clinical trials for patients with head and neck cancers and caregivers.

Six years after a colon cancer diagnosis, Carla Deschamps reflects on growth, independence and optimism shaped by survivorship.

CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

Adding Xofigo to Xtandi extends survival and delays disease progression in men with metastatic castration-resistant prostate cancer with bone involvement.

CAPItello-281 shows Truqap plus Zytiga extends rPFS in PTEN-deficient mHSPC with manageable toxicity and preserved overall quality of life.

Subcutaneous Rybrevant plus Keytruda led to a 56% response rate in recurrent or metastatic head and neck cancer in OrigAMI-4.

FDA approved Hernexeos for untreated HER2-mutant NSCLC after 76% of patients had tumor shrinkage in clinical trial data.

The landscape of relapsed or refractory multiple myeloma (RRMM) treatment is shifting toward a more targeted future, as Dr. Sagar Lonial explained.

Daily practices help one writer find calm and stability while living with multiple myeloma.

Experts share what patients should know from the 2026 ASCO GU Cancer Symposium, highlighting biomarkers, trial options and personalized care decisions.

The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after immunotherapy and platinum.

Lauren Yerkes shares how her breast cancer diagnosis uncovered generations of genetic information for her family.